SillaJen said that Emtuen paid ￦60 billion for 18.75 million shares.

Emtuen will become SillaJen's new largest shareholder starting with the payment, seeking to normalize its management and strengthen its expertise in bio-industry companies. On the 13th of next month, SillaJen will hold an extraordinary shareholders' meeting at the Korea Broadcasting Center in Yangcheon-gu, Seoul and appoint new board members.

According to SillaJen, the new board consists of people who can normalize management and develop bio expertise. GreenFireBio.LLC personnel, a U.S. drug development company with Emtuen as the largest shareholder, are also expected to join the board of directors of SillaJen.
<